269 related articles for article (PubMed ID: 28201598)
1. A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency.
Chatelain P; Malievskiy O; Radziuk K; Senatorova G; Abdou MO; Vlachopapadopoulou E; Skorodok Y; Peterkova V; Leff JA; Beckert M;
J Clin Endocrinol Metab; 2017 May; 102(5):1673-1682. PubMed ID: 28201598
[TBL] [Abstract][Full Text] [Related]
2. Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.
Zelinska N; Iotova V; Skorodok J; Malievsky O; Peterkova V; Samsonova L; Rosenfeld RG; Zadik Z; Jaron-Mendelson M; Koren R; Amitzi L; Raduk D; Hershkovitz O; Hart G
J Clin Endocrinol Metab; 2017 May; 102(5):1578-1587. PubMed ID: 28323965
[TBL] [Abstract][Full Text] [Related]
3. A first-in-man phase 1 trial for long-acting TransCon Growth Hormone.
Gilfoyle D; Mortensen E; Christoffersen ED; Leff JA; Beckert M
Growth Horm IGF Res; 2018 Apr; 39():34-39. PubMed ID: 29273485
[TBL] [Abstract][Full Text] [Related]
4. Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial.
Sävendahl L; Battelino T; Brod M; Højby Rasmussen M; Horikawa R; Juul RV; Saenger P;
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1847-61. PubMed ID: 31917835
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency.
Höybye C; Pfeiffer AF; Ferone D; Christiansen JS; Gilfoyle D; Christoffersen ED; Mortensen E; Leff JA; Beckert M
Endocr Connect; 2017 Apr; 6(3):129-138. PubMed ID: 28196799
[TBL] [Abstract][Full Text] [Related]
6. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
[TBL] [Abstract][Full Text] [Related]
7. Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.
Thornton PS; Maniatis AK; Aghajanova E; Chertok E; Vlachopapadopoulou E; Lin Z; Song W; Christoffersen ED; Breinholt VM; Kovalenko T; Giorgadze E; Korpal-Szczyrska M; Hofman PL; Karpf DB; Shu AD; Beckert M
J Clin Endocrinol Metab; 2021 Oct; 106(11):3184-3195. PubMed ID: 34272849
[TBL] [Abstract][Full Text] [Related]
8. An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment.
Zadik Z; Zelinska N; Iotova V; Skorodok Y; Malievsky O; Mauras N; Valluri SR; Pastrak A; Rosenfeld R
J Pediatr Endocrinol Metab; 2023 Mar; 36(3):261-269. PubMed ID: 36732285
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
Moore WV; Nguyen HJ; Kletter GB; Miller BS; Rogers D; Ng D; Moore JA; Humphriss E; Cleland JL; Bright GM
J Clin Endocrinol Metab; 2016 Mar; 101(3):1091-7. PubMed ID: 26672637
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study.
Horikawa R; Tanaka T; Hasegawa Y; Yorifuji T; Ng D; Rosenfeld RG; Hoshino Y; Okayama A; Shima D; Gomez R; Pastrak A; Castellanos O
Horm Res Paediatr; 2022; 95(3):275-285. PubMed ID: 35417909
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
[TBL] [Abstract][Full Text] [Related]
12. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children.
Cohen P; Germak J; Rogol AD; Weng W; Kappelgaard AM; Rosenfeld RG;
J Clin Endocrinol Metab; 2010 May; 95(5):2089-98. PubMed ID: 20207829
[TBL] [Abstract][Full Text] [Related]
13. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment.
Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M
J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis.
Mameli C; Orso M; Calcaterra V; Wasniewska MG; Aversa T; Granato S; Bruschini P; Guadagni L; d'Angela D; Spandonaro F; Polistena B; Zuccotti G
Pharmacol Res; 2023 Jul; 193():106805. PubMed ID: 37236413
[TBL] [Abstract][Full Text] [Related]
15. Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3.
Sävendahl L; Battelino T; Højby Rasmussen M; Brod M; Saenger P; Horikawa R
J Clin Endocrinol Metab; 2022 Apr; 107(5):1357-1367. PubMed ID: 34964458
[TBL] [Abstract][Full Text] [Related]
16. Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH.
Miller BS; Blair JC; Rasmussen MH; Maniatis A; Mori J; Böttcher V; Kim HS; Bang RB; Polak M; Horikawa R
J Clin Endocrinol Metab; 2023 Nov; 108(12):3090-3099. PubMed ID: 37406251
[TBL] [Abstract][Full Text] [Related]
17. Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial.
Miller BS; Blair JC; Rasmussen MH; Maniatis A; Kildemoes RJ; Mori J; Polak M; Bang RB; Böttcher V; Stagi S; Horikawa R
J Clin Endocrinol Metab; 2022 Nov; 107(12):3378-3388. PubMed ID: 36062966
[TBL] [Abstract][Full Text] [Related]
18. Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial.
Johannsson G; Gordon MB; Højby Rasmussen M; Håkonsson IH; Karges W; Sværke C; Tahara S; Takano K; Biller BMK
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1358-76. PubMed ID: 32022863
[TBL] [Abstract][Full Text] [Related]
19. Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults.
Ku CR; Brue T; Schilbach K; Ignatenko S; Magony S; Chung YS; Kim BJ; Hur KY; Kang HC; Kim JH; Kim MS; Kowalska A; Bolanowski M; Ruchala M; Damjanovic S; Payer J; Choi YJ; Heo SJ; Kim TK; Heo M; Lee J; Lee EJ
Eur J Endocrinol; 2018 Sep; 179(3):169-179. PubMed ID: 29973375
[TBL] [Abstract][Full Text] [Related]
20. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.
Luo X; Hou L; Liang L; Dong G; Shen S; Zhao Z; Gong CX; Li Y; Du ML; Su Z; Du H; Yan C
Eur J Endocrinol; 2017 Aug; 177(2):195-205. PubMed ID: 28566441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
